ezetimibe has been researched along with HIV Coinfection in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avendano, EE; Morin, RA; Nirmala, N | 1 |
| Kazimuddin, M; Mittal, S; Singh, A | 1 |
| Boccara, F; Rosenson, RS | 1 |
| Boonthos, K; Manosuthi, W; Pengsuparp, T; Puttilerpong, C | 1 |
| Fichtenbaum, CJ; Gebhardt, A | 1 |
| Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L | 1 |
| Cofán, M; Forga, MT; Larrousse, M; Leyes, P; Martínez, E; Pérez-Heras, AM; Ros, E; Trabal, J | 1 |
| Sekhar, RV | 1 |
| Bennett, MT; Bondy, G; Frohlich, J; Johns, K; Saeedi, R | 1 |
| Lüscher, TF | 1 |
| Eron, JJ; Hsue, P; Keys, J; Napravnik, S; Richard, S; Schnell, A; Simpson, RJ; Waters, D; Wohl, DA | 1 |
| Asghar, AK; Bower, M; Holmes, P; Isenman, HL; Nelson, M; Stebbing, J | 1 |
| Andersen, J; Busti, A; Chen, H; Chow, D; Glesby, MJ; Kohrs, S; Koletar, SL; Souza, S; Wu, J | 1 |
| Colquhoun, D; Hamilton-Craig, I; Kostner, K; Woodhouse, S | 1 |
| Desta, Z; Hubeny, A; Jia, J; Keiser, M; Kroemer, HK; Lütjohann, D; Marinova, M; Meyer zu Schwabedissen, HE; Modess, C; Mostertz, J; Nassif, A; Ogburn, ET; Oswald, S; Runge, D; Siegmund, W; Ulrich, A | 1 |
| Colotto, M; Durante, C; Renzi, A | 1 |
| Blanco, A; Bonjoch, A; Cinquegrana, D; Clotet, B; López-Blázquez, R; Moltó, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Rey-Joly, C | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
4 review(s) available for ezetimibe and HIV Coinfection
| Article | Year |
|---|---|
Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidaemia: a systematic review and meta-analysis.
Topics: Ezetimibe; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias | 2022 |
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Assessment | 2019 |
Treatment of dyslipidemia in HIV.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides | 2015 |
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
6 trial(s) available for ezetimibe and HIV Coinfection
| Article | Year |
|---|---|
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2014 |
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.
Topics: Anticholesteremic Agents; Demography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; HIV Infections; Humans; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome | 2015 |
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Azetidines; Cholesterol, LDL; Ezetimibe; Female; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos | 2008 |
Use of ezetimibe during HIV infection.
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; HIV Infections; Humans; Hypercholesterolemia; Treatment Outcome | 2009 |
Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.
Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; CD4 Lymphocyte Count; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged | 2009 |
Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
Topics: Adult; Alkynes; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzoxazines; Biological Transport; Cell Line; Cell Line, Transformed; Cyclopropanes; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; Ezetimibe; Gene Expression; Glucuronosyltransferase; HEK293 Cells; HIV Infections; Humans; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; RNA, Messenger; Young Adult | 2012 |
10 other study(ies) available for ezetimibe and HIV Coinfection
| Article | Year |
|---|---|
Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Dyslipidemias; Ezetimibe; HIV Infections; Humans | 2020 |
Reply: Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Dyslipidemias; Ezetimibe; HIV Infections; Humans | 2020 |
Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Ezetimibe; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Thailand | 2018 |
Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged; Phytosterols; Protease Inhibitors | 2014 |
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Obesity; PCSK9 Inhibitors; Testosterone | 2016 |
Ezetimibe lowers cholesterol levels.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; CD4 Lymphocyte Count; Cholesterol, LDL; Ezetimibe; Female; HIV Infections; Humans; Male; Middle Aged; Viral Load | 2009 |
Into the wardrobe of Narnia: beyond HIV infection a world of cardiovascular risk.
Topics: Acromegaly; Adenoma; Adult; Azetidines; Cardiovascular Diseases; Coinfection; Ezetimibe; Female; Fluorobenzenes; Hepatitis C; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Magnetic Resonance Imaging; Pituitary Neoplasms; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; Dyslipidemias; Ezetimibe; Female; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Prospective Studies; Treatment Outcome | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |